avastin
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma
November 19, 2018Sales and Marketing Cancer, Roche, avastin, pharma, renal cell carcinoma, tecentriq
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with …
Novartis and Bayer seek to oppose High Court ruling over NHS decision to use cheaper drug
October 16, 2018Manufacturing and Production Bayer, CCG, NHS, Novartis, avastin, wet AMD
Swiss multinational Novartis have joined German pharma firm Bayer in appealing a High Court ruling over 12 NHS clinical commissioning …
Courts back NHS in fight against Novartis and Bayer
September 24, 2018Sales and Marketing Bayer, Eylea, NHS, Novartis, avastin, ludentis
The NHS has won a court case against multinational pharmaceutical firms Novartis and Bayer, after the companies sought to block …
Roche unveils strong combination treatment data in lung cancer
November 20, 2017Research and Development, Sales and Marketing Cancer, NSCLC< lung cancer, Roche, avastin, immunotherapy, pharma, tecentriq
Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq (atezolizumab) in combination with …
FDA approves first-ever biosimilar for cancer treatment
September 15, 2017Medical Communications, Sales and Marketing Amgen, Cancer, FDA, Mvasi, avastin, biosimilar
The FDA has announced the news that it has awarded approval to the first-ever biosimilar for the treatment of cancer …
Tesaro’s ovarian cancer drug success threatens market rivals
October 12, 2016Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …
Roche says combination therapy with its Avastin and Tarceva gets European backing for lung cancer treatment
June 8, 2016Research and Development, Sales and Marketing European Commission, NSCL, RegulationC, Roche, Tarceva, avastin, drug trial, lung cancer
Cancer drugmaker Roche (SIX: ROG) on Wednesday said the European Commission has approved its Avastin (bevacizumab) in combination with Tarceva …
Roche beats estimates with strong 2015 sales
January 28, 2016Medical Communications, Sales and Marketing Esbriet, Herceptin, Roche, avastin
Roche reported full-year financial results today, beating analysts’ estimates, with the Swiss drugmaker announcing Group sales increases for 2015 in …
Cancer Drugs Fund ‘not sustainable in current form’
September 17, 2015CDF, Cancer Drugs Fund, Department of Health, NHS England, National Audit Office, Public Accounts Committe, Roche, avastin
The Cancer Drugs Fund has improved access to treatments, although the UK still lags behind other countries despite its ‘unsustainable’ …
New treatment option for ovarian cancer patients in Scotland
September 8, 2015Medical Communications, Research and Development, Sales and Marketing Roche, Scotland, avastin, ovarian cancer
The Scottish Medicines Consortium (SMC) has approved the use of Avastin in combination with paclitaxel chemotherapy as a treatment for women …
EU nod for Roche cancer drug and chemotherapy
April 8, 2015Sales and Marketing Cancer, Roche, avastin, bevacizumab, cervical, chemotherapy, wet AMD
The European Commission has approved Roche’s Avastin in combination with standard chemotherapy for women with advanced cervical cancer. Avastin (bevacizumab) …
Novartis accused of Lucentis ‘campaign’ against Avastin
April 2, 2015Sales and Marketing Lucentis, NHS, Novartis, avastin, bevacizumab, ranibizumab, wet AMD
Novartis “embarked on a campaign to undermine and divert attention” from a cheap drug for vision loss and maintain the …
Roche oncology sales shine but profits dip
January 29, 2015Sales and Marketing Kadcyla, Perjeta, Roche, avastin, fourth quarter, oncology, q4
Roche has posted a mixed bag of financial results complemented only by strong growth in its oncology and immunology divisions. …
Government rips up blank cheque on cancer drugs
August 28, 2014Medical Communications, Sales and Marketing Cancer Drugs Fund, Kadclya, Roche, avastin, sovaldi
Pharma has priced itself out of the Cancer Drugs Fund as the rising costs of its new oncology treatments sees …
Latest content
Five Facts about cardiovascular disease
